Orit Itzhaki

2.9k total citations
60 papers, 2.1k citations indexed

About

Orit Itzhaki is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Orit Itzhaki has authored 60 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 28 papers in Immunology and 21 papers in Molecular Biology. Recurrent topics in Orit Itzhaki's work include CAR-T cell therapy research (42 papers), Immunotherapy and Immune Responses (21 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Orit Itzhaki is often cited by papers focused on CAR-T cell therapy research (42 papers), Immunotherapy and Immune Responses (21 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Orit Itzhaki collaborates with scholars based in Israel, United States and Australia. Orit Itzhaki's co-authors include Michal J. Besser, Jacob Schachter, Gal Markel, Adva Kubi, Avraham J. Treves, Ronnie Shapira‐Frommer, Arnon Nagler, Bruria Shalmon, Daphna Levy and Elad Jacoby and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Orit Itzhaki

58 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Orit Itzhaki Israel	22	1.7k	1.2k	627	364	204	60	2.1k
Carmen S. Yong Australia	12	1.2k 0.7×	848 0.7×	455 0.7×	313 0.9×	179 0.9×	21	1.7k
Dhanalakshmi Chinnasamy United States	16	1.6k 1.0×	1.0k 0.9×	778 1.2×	580 1.6×	164 0.8×	25	2.2k
Liang‐Chuan S. Wang United States	15	1.7k 1.0×	949 0.8×	637 1.0×	393 1.1×	199 1.0×	21	2.2k
Christel Devaud Australia	16	1.4k 0.8×	1.0k 0.8×	441 0.7×	322 0.9×	79 0.4×	27	1.9k
Robert J. Schmittling United States	18	1.4k 0.8×	1.3k 1.1×	570 0.9×	177 0.5×	222 1.1×	31	2.5k
Clare Y. Slaney Australia	23	1.8k 1.1×	1.2k 1.0×	761 1.2×	304 0.8×	257 1.3×	38	2.6k
Sherly Mardiana Australia	12	1.2k 0.7×	824 0.7×	444 0.7×	256 0.7×	69 0.3×	13	1.5k
Evripidis Lanitis Switzerland	19	1.6k 0.9×	887 0.7×	695 1.1×	367 1.0×	203 1.0×	25	2.2k
Giacomo Oliveira Italy	14	854 0.5×	802 0.7×	405 0.6×	237 0.7×	77 0.4×	26	1.4k
Bruno L. Cadilha Germany	10	945 0.6×	560 0.5×	393 0.6×	183 0.5×	97 0.5×	16	1.3k

Countries citing papers authored by Orit Itzhaki

Since Specialization

Citations

This map shows the geographic impact of Orit Itzhaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Orit Itzhaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Orit Itzhaki more than expected).

Fields of papers citing papers by Orit Itzhaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Orit Itzhaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Orit Itzhaki. The network helps show where Orit Itzhaki may publish in the future.

Co-authorship network of co-authors of Orit Itzhaki

This figure shows the co-authorship network connecting the top 25 collaborators of Orit Itzhaki. A scholar is included among the top collaborators of Orit Itzhaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Orit Itzhaki. Orit Itzhaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2025). Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Advances. 9(7). 1720–1725. 1 indexed citations

Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2024). Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Current Research in Translational Medicine. 72(4). 103471–103471. 5 indexed citations

Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations

Fried, Shalev, Ivetta Danylesko, Orit Itzhaki, et al.. (2023). High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6875–6875.

Fried, Shalev, Orit Itzhaki, Ronit Yerushalmi, et al.. (2023). Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leukemia & lymphoma. 64(12). 1956–1963. 3 indexed citations

Markovits, Ettai, Erez N. Baruch, Eldad D. Shulman, et al.. (2023). MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2. Cancer Immunology Research. 11(7). 909–924. 8 indexed citations

Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2023). P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION. HemaSphere. 7(S3). e4369964–e4369964. 1 indexed citations

Fried, Shalev, Roni Shouval, Nira Varda‐Bloom, et al.. (2022). Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia & lymphoma. 63(14). 3385–3393. 5 indexed citations

Itzhaki, Orit, Elad Jacoby, Arnon Nagler, et al.. (2020). Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. Journal for ImmunoTherapy of Cancer. 8(1). e000148–e000148. 37 indexed citations

10.

Galore-Haskel, Gilli, Eyal Greenberg, Inbal Yahav, et al.. (2020). microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. Cancer Immunology Immunotherapy. 70(6). 1541–1555. 6 indexed citations

11.

Levin, Noam, Orit Itzhaki, Michal J. Besser, et al.. (2018). Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. The Journal of Immunology. 201(10). 2959–2968. 12 indexed citations

12.

Merhavi-Shoham, Efrat, Orit Itzhaki, Gal Markel, Jacob Schachter, & Michal J. Besser. (2017). Adoptive Cell Therapy for Metastatic Melanoma. The Cancer Journal. 23(1). 48–53. 46 indexed citations

13.

Levin, Noam, Orit Itzhaki, Michal J. Besser, et al.. (2016). Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants. Journal of Immunotherapy. 39(2). 60–70. 20 indexed citations

14.

Ortenberg, Rona, Sivan Sapoznik, Douglas Zippel, et al.. (2015). Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy. Journal of Immunology Research. 2015. 1–8. 12 indexed citations

15.

Besser, Michal J., Ronnie Shapira‐Frommer, Orit Itzhaki, et al.. (2013). Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clinical Cancer Research. 19(17). 4792–4800. 294 indexed citations

16.

Greenberg, Eyal, Michal J. Besser, Eytan Ben‐Ami, et al.. (2013). A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 18(6). 502–508. 39 indexed citations

17.

Besser, Michal J., Ronnie Shapira‐Frommer, Avraham J. Treves, et al.. (2010). Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research. 16(9). 2646–2655. 352 indexed citations

18.

Markel, Gal, Michal J. Besser, Kfir Oved, et al.. (2009). Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.. PubMed. 29(1). 145–54. 33 indexed citations

19.

Keshet, Gilmor I., Itamar Goldstein, Orit Itzhaki, et al.. (2008). MDR1 expression identifies human melanoma stem cells. Biochemical and Biophysical Research Communications. 368(4). 930–936. 87 indexed citations

20.

Itzhaki, Orit, et al.. (2003). Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1688(2). 145–159. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact